Apogee Therapeutics Inc.
Apogee Therapeutics Announces Positive Clinical Trial Results for APG777
Summary
On July 7, 2025, Apogee Therapeutics, Inc. announced positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, its anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). The trial met its primary endpoint with a significant reduction in EASI score. Additionally, the first patient was dosed in a Phase 1b head-to-head trial of APG279 against DUPIXENT, with results expected in the second half of 2026. These announcements were made pursuant to Regulation FD.
Profitelligence Alerts
Get alerts for APGE
Be first to know when Apogee Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Apogee Therapeutics Inc.
Apogee Therapeutics Inc. is a biotechnology company focused on the development of biologic therapies for atopic dermatitis and other inflammatory diseases. The primary purpose of Apogee Therapeutics is to leverage its expertise in immunology and protein engineering to address unmet needs in the treatment of autoimmune and inflammatory conditions. The company is active in sectors such as healthcare and pharmaceuticals, contributing to advancements in medical biotechnology. Apogee Therapeutics plays a significant role in the financial market by advancing cutting-edge therapies in the biopharmaceutical landscape. It engages in research and development efforts to bring innovative biologic medicines to patients, thereby impacting the broader pharmaceutical industry. The company's focus on treating inflammatory diseases aligns with an increasing demand for novel treatments arising from a greater understanding of disease mechanisms and patient needs. By developing specialized biologic solutions, Apogee Therapeutics positions itself as a key player in addressing some of the challenges associated with chronic inflammatory conditions, ultimately pushing forward the boundaries of therapeutic options available to patients worldwide.
Official SEC Documents
Advertisement